Literature DB >> 18514579

Immune responses during acute and chronic infection with hepatitis C virus.

Shigeaki Ishii1, Margaret James Koziel.   

Abstract

Hepatitis C virus (HCV) induces persistent infection and causes chronic liver disease in most infected patients. Vigorous HCV-specific CD4+ and CD8+ T cell responses against HCV multiple epitopes are necessary for spontaneous viral clearance during the acute phase, but the virus appears to have multiple strategies to evade these defenses. There are relatively few studies on the role of immune responses during the chronic phase of infection. CD4+ T cell responses appear to protect against liver injury and may be important to clearance during interferon and ribavirin based therapy. Classic cytotoxic T cells (CTL) may primarily damage the liver in chronic HCV, but there may be subpopulations of T cells that protect against liver inflammation. Resolution of these outstanding questions is important to the development of a prophylactic vaccine as well as improving therapeutic options for those with chronic infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18514579      PMCID: PMC4405177          DOI: 10.1016/j.clim.2008.03.525

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  217 in total

1.  Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C.

Authors:  Randy S Longman; Andrew H Talal; Ira M Jacobson; Charles M Rice; Matthew L Albert
Journal:  J Infect Dis       Date:  2005-06-27       Impact factor: 5.226

2.  Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection.

Authors:  D K Wong; D D Dudley; N H Afdhal; J Dienstag; C M Rice; L Wang; M Houghton; B D Walker; M J Koziel
Journal:  J Immunol       Date:  1998-02-01       Impact factor: 5.422

3.  Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression.

Authors:  Henry Radziewicz; Chris C Ibegbu; Marina L Fernandez; Kimberly A Workowski; Kamil Obideen; Mohammad Wehbi; Holly L Hanson; James P Steinberg; David Masopust; E John Wherry; John D Altman; Barry T Rouse; Gordon J Freeman; Rafi Ahmed; Arash Grakoui
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

4.  Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins.

Authors:  Pablo Sarobe; Juan José Lasarte; Noelia Casares; Ascensión López-Díaz de Cerio; Elena Baixeras; Pablo Labarga; Nicolás García; Francisco Borrás-Cuesta; Jesús Prieto
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

5.  T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection.

Authors:  Tobias Boettler; Hans Christian Spangenberg; Christoph Neumann-Haefelin; Elisabeth Panther; Simonetta Urbani; Carlo Ferrari; Hubert E Blum; Fritz von Weizsäcker; Robert Thimme
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

6.  Chronic hepatitis C virus infection established and maintained in chimpanzees independent of dendritic cell impairment.

Authors:  Christine Rollier; Joost A R Drexhage; Babs E Verstrepen; Ernst J Verschoor; Ronald E Bontrop; Gerrit Koopman; Jonathan L Heeney
Journal:  Hepatology       Date:  2003-10       Impact factor: 17.425

7.  Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus.

Authors:  Thomas P Giordano; Louise Henderson; Ola Landgren; Elizabeth Y Chiao; Jennifer R Kramer; Hashem El-Serag; Eric A Engels
Journal:  JAMA       Date:  2007-05-09       Impact factor: 56.272

8.  Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation.

Authors:  Karla J Helbig; Andrew Ruszkiewicz; Ljiljana Semendric; Hugh A J Harley; Shaun R McColl; Michael R Beard
Journal:  Hepatology       Date:  2004-05       Impact factor: 17.425

9.  Increased intrahepatic messenger RNA expression of interleukins 2, 6, and 8 in human cirrhosis.

Authors:  J Napoli; G A Bishop; G W McCaughan
Journal:  Gastroenterology       Date:  1994-09       Impact factor: 22.682

10.  Analysis of successful immune responses in persons infected with hepatitis C virus.

Authors:  F Lechner; D K Wong; P R Dunbar; R Chapman; R T Chung; P Dohrenwend; G Robbins; R Phillips; P Klenerman; B D Walker
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307

View more
  27 in total

1.  Characteristics of chronic hepatitis C among intravenous drug users: a comparative analysis.

Authors:  Maja Jovanović; Branislav Jovanović; Milena Potić; Ljiljana Konstantinović; Miodrag Vrbić; Biljana Radovanović-Dinić; Velimir Kostić
Journal:  Bosn J Basic Med Sci       Date:  2010-05       Impact factor: 3.363

2.  Natural evolution of hepatitis C virus infection in hemodialysis Tunisian patients and CTLA-4 SNP's.

Authors:  Leila Ksiaa Cheikhrouhou; Yousr Lakhoua-Gorgi; Imen Sfar; Salwa Jendoubi-Ayed; Houda Aouadi; Mouna Makhlouf; Khaled Ayed; Taieb Ben Abdallah
Journal:  World J Gastroenterol       Date:  2015-09-21       Impact factor: 5.742

3.  Human T cell microparticles circulate in blood of hepatitis patients and induce fibrolytic activation of hepatic stellate cells.

Authors:  Miroslaw Kornek; Yury Popov; Towia A Libermann; Nezam H Afdhal; Detlef Schuppan
Journal:  Hepatology       Date:  2010-10-26       Impact factor: 17.425

Review 4.  Vaccinomics and a new paradigm for the development of preventive vaccines against viral infections.

Authors:  Gregory A Poland; Inna G Ovsyannikova; Richard B Kennedy; Iana H Haralambieva; Robert M Jacobson
Journal:  OMICS       Date:  2011-07-06

5.  Construction of HCV-polytope vaccine candidates harbouring immune-enhancer sequences and primary evaluation of their immunogenicity in BALB/c mice.

Authors:  Arash Arashkia; Farzin Roohvand; Arash Memarnejadian; Mohammad Reza Aghasadeghi; Sima Rafati
Journal:  Virus Genes       Date:  2009-10-31       Impact factor: 2.332

6.  Identification and retrospective validation of T-cell epitopes in the hepatitis C virus genotype 4 proteome: an accelerated approach toward epitope-driven vaccine development.

Authors:  Karim M Abdel-Hady; Andres H Gutierrez; Frances Terry; Joe Desrosiers; Anne S De Groot; Hassan M E Azzazy
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

7.  Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis.

Authors:  Daniel Sepulveda-Crespo; Salvador Resino; Isidoro Martinez
Journal:  Drugs       Date:  2021-01-05       Impact factor: 9.546

Review 8.  Progress in the development of vaccines for hepatitis C virus infection.

Authors:  Faezeh Ghasemi; Sina Rostami; Zahra Meshkat
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

9.  Toll-like receptors as targets in chronic liver diseases.

Authors:  A Mencin; J Kluwe; R F Schwabe
Journal:  Gut       Date:  2009-05       Impact factor: 23.059

Review 10.  Immune dysregulation in human immunodeficiency virus infection: know it, fix it, prevent it?

Authors:  A Boasso; G M Shearer; C Chougnet
Journal:  J Intern Med       Date:  2009-01       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.